Who should be tested?

• Treatment eligible
• Metastatic disease
  
  

When and what should be tested?

• At time of initial diagnosis 
• Recurrence
• Tissue or liquid
  
  

What tests should be considered?

• NCCN/FDA Approved
  • dMMR/MSI-H
  • NTRK * FGF
• Emerging Biomarkers
  •  IDH1
  • IDH2
  • FGF
  • KRAS
  • Expanded NGS panel
• Informational considerations: 
  •  FGF